HES6 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the HES6 gene. This product consists of a heterogeneous mixture of HEK293T cells with CRISPR/Cas9-mediated gene disruptions, providing a robust model for investigating HES6 function without the clonal selection artifacts of single-cell-derived lines. The polyclonal format enables bulk population analyses, reflecting a spectrum of editing events and offering a cost-effective approach to assess overall signaling and phenotypic changes. Researchers can utilize this resource to examine HES6-dependent transcriptional regulation, Notch pathway modulation, and cell fate control in a well-characterized host background.
HEK293T cells are a widely used human embryonic kidney epithelial cell line that constitutively expresses the SV40 large T antigen, enhancing episomal plasmid replication and yielding exceptionally high transfection efficiencies. Derived from HEK293 cells transformed with sheared adenovirus type 5 DNA, these adherent cells have become a standard platform for functional genomics, protein expression, and pathway analysis. Their rapid proliferation, ease of culture, and compatibility with a broad range of molecular assays make them an ideal host for generating knockout models. The HEK293T background supports robust expression of many signaling components, including Notch pathway members, facilitating mechanistic studies of HES6.
HES6 encodes a basic helix-loop-helix (bHLH) transcription factor that serves as a negative regulator of HES1, a key downstream effector of the Notch pathway. Mechanistically, HES6 heterodimerizes with HES1, blocking its homodimerization and subsequent binding to N-box DNA sequences, thereby derepressing proneural genes such as NEUROD1, ASCL1, and NEUROG2. In canonical Notch signaling, ligands like DLL1 and JAG1 engage NOTCH1 receptors, triggering proteolytic release of the Notch intracellular domain (NICD). NICD translocates to the nucleus, forms a complex with RBPJ and MAML, and activates transcription of HES1 and HEY1. HES6 antagonizes this repression, promoting neuronal differentiation and influencing cell fate. Upstream regulators including NICD, proneural bHLH factors (NEUROG2, ASCL1), and BMP signaling modulate HES6 expression, positioning it at a critical junction between proliferation and differentiation.
In the HEK293T context, HES6 knockout removes a crucial brake on HES1-mediated transcriptional repression, leading to enhanced Notch pathway activity. Although these cells are non-neuronal, they express a functional Notch signaling network, making them an excellent model for dissecting protein-protein interactions and transcriptional outputs. The polyclonal knockout population provides a broad representation of disrupted alleles, allowing researchers to evaluate net pathway shifts while minimizing biases from individual clones. This model is particularly valuable for studying HES6’s roles in cancer biology, given its dysregulation in glioblastoma and prostate cancer, where it may influence tumor cell proliferation and differentiation.
This knockout model enables a wide range of experimental applications, including Western blotting to quantify HES1 and downstream target proteins, RT-qPCR to measure transcriptional changes in proneural genes, and Notch pathway luciferase reporter assays to directly assess signaling activity. Co-immunoprecipitation experiments can be conducted to probe HES1-HES6 heterodimerization, while proliferation assays reveal functional consequences of HES6 loss. The cells are well-suited for drug screening campaigns targeting the Notch pathway and for mechanistic studies of neurogenesis and cell fate determination. For additional information or technical support, please contact Ascent Research.
